Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma

Bathe, Oliver F.; Dowden, Scot; Sutherland, Francis; Dixon, Elijah; Butts, Charles; Bigam, David L.; Walley, Barbara; Ruether, Dean; Ernst, Scott

doi:10.1186/1471-2407-4-32

Cited by 32 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, it can be useful to determine the necessity of intensive follow-up and adjuvant therapy for CRC by predicting recurrence and metastases in curative surgical resection (Bathe et al, 2004;Kornmann et al, 2008;Wolpin and Mayer, 2008). In this study, clinico-pathological analysis revealed that TRIB3 is closely related to metastasis, but not to lymphatic metastasis.…”

Section: Discussionmentioning

confidence: 73%

“…In gastrointestinal cancer therapy, it is essential to prevent metachronous metastasis. Several adjuvant chemotherapies are helpful in certain disease stages, especially in CRC (Bathe et al, 2004;Andre et al, 2007). Recently, increasing evidence has been accumulated, showing the usefulness of less invasive surgery in the treatment of CRC, such as laparoscopic and endoscopic surgery (Lacy et al, 2002;Weeks et al, 2002;Clinical Outcomes of Surgical Therapy Study Group, 2004;Jayne et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: TRIB3 is a human homologue of Drosophila tribbles. Previous studies have shown that TRIB3 controls the cell growth through ubiquitination-dependent degradation of other proteins, whereas its significance in the prognosis of colorectal cancer (CRC) is not yet fully understood. MATERIALS: This study comprised 202 patients who underwent surgery for CRC, as well as 22 cell lines derived from human gastrointestinal cancer. The correlation of gene expression with clinical parameters in patients was assessed. The biological significance was evaluated by knockdown experiments in seven colorectal cancer cell lines. RESULTS: A total of 20 cancer cell lines (90.9%) expressed the TRIB3 gene. The assessment in surgical specimens indicated that the gene expression was significantly higher in the cancerous region than in the marginal non-cancerous region. Patients with high TRIB3 expression were statistically susceptible to a recurrence of the disease, and showed poorer overall survival than those with low expression. The assessment of TRIB3 knockdown in five cell lines showed that small interfering RNA (siRNA) inhibition resulted in a statistically significant reduction in cell growth. CONCLUSION: These data strongly suggest the usefulness of TRIB3 as a marker for predicting the prognosis of CRC patients, showing a basis for the development of effective treatments for CRC.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis

et al. 2009

View full text Add to dashboard Cite

show abstract

“…8,12 As such, models to predict the prognosis after curative surgical resection would be useful to determine the necessity of intensive follow-up to select adjuvant therapy. Although the choice of adjuvant chemotherapies was excluded from the analyses of the present study due to multicollinearity in relation to the lymph node metastatic statuses, clinicopathologic analysis revealed that the tumor In this study, they were categorized as M1a according to the TNM classification of UICC.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…[12][13][14][15] Patients with localized metastases, such as liver or lung, can achieve long-term survival through curative resection of the metastatic lesions. 8,12 As such, models to predict the prognosis after curative surgical resection would be useful to determine the necessity of intensive follow-up to select adjuvant therapy. Although the choice of adjuvant chemotherapies was excluded from the analyses of the present study due to multicollinearity in relation to the lymph node metastatic statuses, clinicopathologic analysis revealed that the tumor Poorly differentiated, mucinous adenocarcinoma, or signet-ring cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Prediction Models for Colorectal Cancer Patients After Curative Resection

Miyoshi

Ohue

Noura

et al. 2016

International Surgery

View full text Add to dashboard Cite

To develop a prediction tool for recurrence and survival in colorectal cancer (CRC) patients following surgically curative resections. We developed a reliable prediction model for CRC patients after surgically curative resections. Using clinicopathologic factors, novel prediction models were constructed with the area under the curve (AUC) of 0.841 and 0.876 for DFS and CSS, respectively. Between January 2004 and December 2007, 376 CRC patients were investigated at the Osaka Medical Center for Cancer and Cardiovascular Diseases. Patients with at least 1 of the following criteria were excluded: preoperative treatment, synchronous distant metastasis, noncurative resection, and incomplete follow-up after operation. All patients were retrospectively analyzed. A Cox proportional hazards model was used to develop a prediction model for disease-free survival (DFS) and cancer-specific survival (CSS). In univariate and multivariate analyses of clinicopathologic factors, the following factors had significant correlation with DFS and CSS: tumor location, preoperative serum carcinoembryonic antigen (CEA), pathologically defined tumor invasion, and lymph node metastasis. Using these variables, novel prediction models were constructed by the logistic regression model with AUC of 0.840 and 0.876 for DFS and CSS, respectively. The prediction models were validated by external datasets in an independent patient group. This study showed novel and reliable personalized prognostic models, integrating not only TNM factors but also tumor location and preoperative serum CEA to predict patient prognosis. These individualized prediction models could help clinicians in the treatment of postoperative CRC patients. Key words: Prediction tool -Colorectal cancer -Metastasis -SurvivalCorresponding author: Norikatsu Miyoshi, MD, PhD, Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1À3À3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan.Tel.: þ81 6 6972 1181, Fax: þ81 6 6981 8055, E-mail: miyosi-no@mc.pref.osaka.jp 406Int Surg 2016;101 I n developed countries with an ever-increasing aging population, cancer is one of the most prominent illnesses in terms of both public welfare and health measures. Colorectal cancer (CRC) is a frequent malignancy and one of the leading causes of cancer-related deaths.1 The metastatic dissemination of the primary tumors directly relates to patient survival, and distant metastases are a major cause of death in CRC. Systemic chemotherapy is the standard approach to treat metastatic CRC, and the last decade showed remarkable progress in therapies for CRC. Many new drugs are currently in use for metastatic CRC, and the average median survival duration has increased in recent years largely due to the availability of new active agents, such as irinotecan, oxaliplatin, cetuximab, and bevacizumab.2-4 Although many patients with metastatic CRC are hard to be cured, a subset of patients with liver-or lung-isolated disease have been reported to be potentially curable with surgery. 5,6 Develo...

show abstract

Colorectal liver metastases contract centripetally with a response to chemotherapy

Urbanski

Mangat

et al. 2007

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND.Recently, there has been considerable interest in neoadjuvant chemotherapy for colorectal liver metastases. However, there is little information that defines how much liver should be removed after a favorable response.METHODS.Liver metastases from 2 groups of patients were analyzed: 25 metastases were evaluated from a group that did not receive chemotherapy and 26 lesions were studied from patients who had received systemic chemotherapy before resection. All patients except for 1 had 5‐fluorouracil (5‐FU), leucovorin (LV), and irinotecan (CPT‐11); 1 had 5‐FU and LV alone. The average duration of chemotherapy was 2.9 ± 0.7 months. Separate assessments of the histopathologic features of the central and peripheral portions of each tumor were made. The pathologist was blinded to all clinical information.RESULTS.All of the untreated metastases had well‐circumscribed borders. Irregular borders were seen in 6 of the postchemotherapy lesions (26%), which was particularly prominent in lesions that had significantly contracted. After chemotherapy, discrete islands of viable tumor cells outside of the main tumor mass were seen in 4 patients, but all were close to the peripheral margin of the tumor mass. Viable tumor cells were more frequent in the periphery of metastases, regardless of chemotherapy exposure. Central necrosis was prominent in untreated metastases, but disappeared after chemotherapy. In lesions treated with chemotherapy, central fibrosis was greater compared with untreated lesions.CONCLUSIONS.After a partial response to chemotherapy, liver metastases shrank in a generally concentric fashion. These findings support the practice of removing less liver after downsizing with chemotherapy. Cancer 2008. © 2007 American Cancer Society.

show abstract

Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma

Cited by 32 publications

References 19 publications

Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis

Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis

Prognostic Prediction Models for Colorectal Cancer Patients After Curative Resection

Colorectal liver metastases contract centripetally with a response to chemotherapy

Contact Info

Product

Resources

About